Skip to content
TrialScanner

NCT04545060

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

Phase 2/Phase 3CompletedVIRLeadGSKCollaborator

Registry record

Lead sponsor
Vir Biotechnology, Inc.
Conditions
Covid19
Primary completion
Apr 8, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04545060 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04545060: VIR-7831 for the Early... | TrialScanner